Eltrombopag for Adults and Children with Immune-Refractory Thrombocytopenic Purpura: A Systematic Review
Eltrombopag is an agonist that binds to the membrane-bound domain of the thrombopoietin receptor used in immune thrombocytopenic purpura (ITP). We conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of eltrombopag in adults and children with refractory ITP. Ad...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/12/3872 |
| _version_ | 1797594135184539648 |
|---|---|
| author | Danielle Francisco Honorato de Barros Torelli Crystian Bitencourt Soares Oliveira Gisele Alborghetti Nai Evelinda Marramon Trindade Luiz Euribel Prestes-Carneiro |
| author_facet | Danielle Francisco Honorato de Barros Torelli Crystian Bitencourt Soares Oliveira Gisele Alborghetti Nai Evelinda Marramon Trindade Luiz Euribel Prestes-Carneiro |
| author_sort | Danielle Francisco Honorato de Barros Torelli |
| collection | DOAJ |
| description | Eltrombopag is an agonist that binds to the membrane-bound domain of the thrombopoietin receptor used in immune thrombocytopenic purpura (ITP). We conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of eltrombopag in adults and children with refractory ITP. Adults who received eltrombopag had a significantly better platelet response (relative risk [RR], 3.65; 95% confidence interval [CI], 2.39–5.55), but there were no differences in the incidence of bleeding (RR, 0.8; 95% CI, 0.52–1.22) and adverse effects (RR, 0.99; 95% CI, 0.55–1.78) compared with the placebo. In children, there was no difference between eltrombopag and placebo for a platelet response >50,000/mm<sup>3</sup> (RR, 3.93; 95% CI, 0.56–27.79) and the number of adverse events (RR, 0.99; 95% CI, 0.25–1.49); however, a lower incidence of bleeding was observed (RR, 0.47; 95% CI, 0.27–0.83). Treatment with eltrombopag protected adults and children from severe disease and death. |
| first_indexed | 2024-03-11T02:19:16Z |
| format | Article |
| id | doaj.art-48b34d8ff8b74658af96399b67e0c1b1 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T02:19:16Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-48b34d8ff8b74658af96399b67e0c1b12023-11-18T10:57:49ZengMDPI AGJournal of Clinical Medicine2077-03832023-06-011212387210.3390/jcm12123872Eltrombopag for Adults and Children with Immune-Refractory Thrombocytopenic Purpura: A Systematic ReviewDanielle Francisco Honorato de Barros Torelli0Crystian Bitencourt Soares Oliveira1Gisele Alborghetti Nai2Evelinda Marramon Trindade3Luiz Euribel Prestes-Carneiro4Master’s Program in Health Sciences, Oeste Paulista University, Presidente Prudente 19050-920, SP, BrazilMaster’s Program in Health Sciences, Oeste Paulista University, Presidente Prudente 19050-920, SP, BrazilMaster’s Program in Health Sciences, Oeste Paulista University, Presidente Prudente 19050-920, SP, BrazilHealth Technology Assessment Center (NATS) of the São Paulo University Medical School, Clinics Hospital, São Paulo 01246-903, SP, BrazilMaster’s Program in Health Sciences, Oeste Paulista University, Presidente Prudente 19050-920, SP, BrazilEltrombopag is an agonist that binds to the membrane-bound domain of the thrombopoietin receptor used in immune thrombocytopenic purpura (ITP). We conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of eltrombopag in adults and children with refractory ITP. Adults who received eltrombopag had a significantly better platelet response (relative risk [RR], 3.65; 95% confidence interval [CI], 2.39–5.55), but there were no differences in the incidence of bleeding (RR, 0.8; 95% CI, 0.52–1.22) and adverse effects (RR, 0.99; 95% CI, 0.55–1.78) compared with the placebo. In children, there was no difference between eltrombopag and placebo for a platelet response >50,000/mm<sup>3</sup> (RR, 3.93; 95% CI, 0.56–27.79) and the number of adverse events (RR, 0.99; 95% CI, 0.25–1.49); however, a lower incidence of bleeding was observed (RR, 0.47; 95% CI, 0.27–0.83). Treatment with eltrombopag protected adults and children from severe disease and death.https://www.mdpi.com/2077-0383/12/12/3872immune thrombocytopenic purpuraerythropoietin receptorssystematic reviewblood coagulationhematologic drugs |
| spellingShingle | Danielle Francisco Honorato de Barros Torelli Crystian Bitencourt Soares Oliveira Gisele Alborghetti Nai Evelinda Marramon Trindade Luiz Euribel Prestes-Carneiro Eltrombopag for Adults and Children with Immune-Refractory Thrombocytopenic Purpura: A Systematic Review Journal of Clinical Medicine immune thrombocytopenic purpura erythropoietin receptors systematic review blood coagulation hematologic drugs |
| title | Eltrombopag for Adults and Children with Immune-Refractory Thrombocytopenic Purpura: A Systematic Review |
| title_full | Eltrombopag for Adults and Children with Immune-Refractory Thrombocytopenic Purpura: A Systematic Review |
| title_fullStr | Eltrombopag for Adults and Children with Immune-Refractory Thrombocytopenic Purpura: A Systematic Review |
| title_full_unstemmed | Eltrombopag for Adults and Children with Immune-Refractory Thrombocytopenic Purpura: A Systematic Review |
| title_short | Eltrombopag for Adults and Children with Immune-Refractory Thrombocytopenic Purpura: A Systematic Review |
| title_sort | eltrombopag for adults and children with immune refractory thrombocytopenic purpura a systematic review |
| topic | immune thrombocytopenic purpura erythropoietin receptors systematic review blood coagulation hematologic drugs |
| url | https://www.mdpi.com/2077-0383/12/12/3872 |
| work_keys_str_mv | AT daniellefranciscohonoratodebarrostorelli eltrombopagforadultsandchildrenwithimmunerefractorythrombocytopenicpurpuraasystematicreview AT crystianbitencourtsoaresoliveira eltrombopagforadultsandchildrenwithimmunerefractorythrombocytopenicpurpuraasystematicreview AT giselealborghettinai eltrombopagforadultsandchildrenwithimmunerefractorythrombocytopenicpurpuraasystematicreview AT evelindamarramontrindade eltrombopagforadultsandchildrenwithimmunerefractorythrombocytopenicpurpuraasystematicreview AT luizeuribelprestescarneiro eltrombopagforadultsandchildrenwithimmunerefractorythrombocytopenicpurpuraasystematicreview |